AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06487195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education group
Description: The psychoeducation group (6 subgroups; 10-12 participants per subgroup) will be led by one experienced psychiatric nurse trained in psychiatric rehabilitation and psychoeducation group programmes.
Study NCT06487195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual only
Description: Participants in the TAU group will receive routine community mental healthcare services.
Study NCT06487195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual only
Description: Participants in the TAU group will receive routine community mental healthcare services.
Study NCT06487195 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual only
Description: Participants in the TAU group will receive routine community mental healthcare services.
Study NCT05137132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CARDIO®
Description: CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA
Study NCT05137132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCT oil
Study NCT04855422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Allosure
Description: AlloSure Analysis For the AlloSure test, 10-20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) at ambient temperature in insulated packaging to minimize temperature fluctuation. The AlloSure test will be performed at the CareDx CLIA/CAP-accredited clinical laboratory. Samples will be tested, and results provided within 3 days of blood draw
Study NCT04855422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AlloMap
Description: AlloMap Kidney is intended to aid in the identification of SPK transplant recipients who have a low probability of rejection at the time in testing in conjunction with standard clinical assessment. For the AlloMap-Kidney test, approximately two tubes of blood will be obtained in PAXgene Blood RNA tubes and shipped to CareDx, Inc. (Brisbane, CA), where it will be tested.
Study NCT05646875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA
Study NCT05646875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA
Study NCT05530174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic dosage practice
Description: Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines.
Study NCT05530174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic dosage practice
Description: Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines.
Study NCT05365321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WP1122
Description: Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
Study NCT05365321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WP1122
Description: Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
Study NCT05483920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-time educational video
Description: One-time educational video
Study NCT05483920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-time educational video plus automated text messaging
Description: Educational video plus automated text messaging
Study NCT06541470 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cutting needle biopsy
Description: Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
Study NCT06541470 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abrams needle biopsy
Description: Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
Study NCT03929211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: Given intravenously, CPI-613 dose will be 2,000 mg/m² and will not escalate.
Study NCT03929211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given by mouth, hydroxychloroquine will be dose escalated from 600 mg to 1,200 mg orally given 2 hours before the CPI-613 infusion on days 1-5 of every 28 day cycle in a 3+3 dose escalation design.
Study NCT05461222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balt Goldballoon
Description: Fetal endoscopic tracheal occlusion (FETO) is a procedure where a balloon is placed in the main airway or windpipe of the fetus, to help with the development of the lungs. This is performed using a fetoscope, a small camera that is inserted into the amniotic cavity and deploying the FETO Goldballoon into the fetal trachea.
Study NCT06052371 — intervention group
Intervention type: DEVICE
Intervention: VerioVue (Enhancements) blood glucose monitoring system
Description: VerioVue meter with expanded haematocrit range
Study NCT04756609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice
Description: I- A SARS-CoV2 self-administered questionnaire about SARS-CoV2 symptoms, possibilities of close contacts, risk exposure situations and socio-demographic characteristics will be offered to patients included who are capable of filling it out.~* The patient will fill out the questionnaire and hand it in to the nurse caring for him/her.~* The nurse, regardless of the answers to the questionnaire, will offer the SARS-CoV2 screening.~* A nasopharyngeal swab for SARS-CoV2 will be carried out.~* A patient will be considered as symptomatic if he/she presents one or more symptoms listed in the questionnaire.~* For symptomatic patients, a SARS-CoV2 for multiplex PCR will be carried out. This analysis takes 75 minutes.~* For asymptomatic patients, a RT-LAMP test will be carried out. This analysis takes 5 to 15 minutes.
Study NCT04756609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual emergency department practice with physician-directed diagnostic testing
Description: The physician offers a SARS-CoV2 test according to current recommendations. The tests are prescribed as a means of diagnosis for patients presenting symptoms suggestive of Covid-19 or as a means of diagnosis for patients requiring hospitalisation for another cause, before their transfer to hospital. Patients will be cared for according to usual procedures of each hospital. Patients tested positive will be asked to fill out the DEPIST-COVID questionnaire. Patients who had not completed it will be contacted by phone to answer the questions over the phone.
Study NCT04817592 — intervention group
Intervention type: PROCEDURE
Intervention: Corneal lenticule extraction for advanced refractive correction (CLEAR)
Description: Routinely conducted procedure for correction of Myopia
Study NCT06358378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia SA Bracelet
Description: The Aktiia device is a wearable blood pressure monitor developed by the company Aktiia SA. It is designed to monitor at blood pressure frequent intervals throughout the day and night without the need for inflatable cuffs. Instead, it contains optical sensors which collect photoplethysmography signals from arteries in the patient's wrist and uses these to estimate blood pressure. The device only takes measurements when it perceived optimal conditions for doing so, corresponding to minimal arm movement (i.e. a resting state) for at least five minutes and good quality signal detection. This device is commercially available and validated for use in adults aged 85 and younger.
Study NCT06578910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: 12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
Study NCT06578910 — intervention group
Intervention type: OTHER
Intervention: Patient satisfaction questionnare
Description: VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
Study NCT05211388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA controlled using echo decorrelation imaging
Description: The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion.~The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume.~To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points.
Study NCT05211388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA controlled using standard manufacturer-specified algorithms
Description: The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.
Study NCT05956288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) with low load resistance training
Description: Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.
Study NCT05956288 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blood flow restriction (BFR) with low load resistance training
Description: Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.
Study NCT04909242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.
Study NCT04909242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.
Study NCT04909242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.
Study NCT04909242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).
Study NCT05964478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component hand hygiene intervention in primary schools not connected to functional water supply system in Nigeria and Palestine
Description: Each participating school receives: (i) Two Gravit'eau handwashing stations (http://www.graviteau.ch): these systems recycle on-site greywater and operate through gravity and a manual foot pump, and can be produced locally. (ii) Behavior change activities: Developed by a group of expert psychologists (http://www.ranasmosler.com/ranas), utilizing the risks, attitudes, norms, abilities, and self-regulation (RANAS) approach. (iii) WASH infrastructure rehabilitation and soap dispenser installation. (iv) Controlled chlorine monitoring: Equipment provided for monitoring chlorine concentration in water storage, with staff training. (v) Preventive maintenance: Trained circuit rider inspects infrastructure regularly under WASH committee supervision
Study NCT05439798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron+Dexamethasone
Description: The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)
Study NCT05439798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron+Dexamethasone
Description: The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)
Study NCT05439798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT05680220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation System (NSS): Active Setting
Description: Exposure to the active device for 1 hour a day for 6 weeks
Study NCT05564013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Up to 25 minutes of virtual reality exposure in supine position
Study NCT05586568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621 tablet and itraconazole oral liquid (for Arm1)
Description: There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.
Study NCT05586568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621 tablet and Rifampicin capsules (For Arm 2)
Description: There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.
Study NCT05586568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621 tablet and esomeprazole tablet (For Arm3)
Description: There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
Study NCT05777330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test (OGTT)
Description: Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~OGTT is performed every 6 months (every 3 months in case of dysglycemia) in all participants.
Study NCT05777330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hyperglycemic clamp test
Description: Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~Clamp test is performed every 12 months in single autoantibody-positive participants and every 6 months in multiple autoantibody-positive participants. Clamp tests are not performed in participants aged between 5-11 years.
Study NCT05777330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~A 10-day CGM recording is performed every 6 months (every 3 months in case of dysglycemia) in all participants.
Study NCT04846959 — intervention group
Intervention type: DRUG
Intervention: Risankizumab
Description: Subcutaneous Injection
Study NCT04846959 — intervention group
Intervention type: DRUG
Intervention: Comparator
Description: Subcutaneous or Intravenous Injection
Study NCT04741308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: The CBT intervention is a 8-times group-based intervention that meets 2-3 weeks.Each session will be performed during chemotherapy and will last for 60 min, including 45 min cognitive behavior therapy and 15 min relaxation training.Our CBT intervention is designed to be conducted in groups of 3 to 6 patients led by two group facilitators. Group leaders will: guide participants relaxation training, develop a supportive group environment, encourage emotional expression, assist participants develop a sense of self-confidence, identify maladaptive coping and encourage adaptive coping responses.
Study NCT06100237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
Study NCT06100237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
Study NCT05680220 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurostimulation System (NSS): Sham Setting
Description: Exposure to the sham device for 1 hour a day for 6 weeks
Study NCT03266315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FloraBaby
Description: 1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
Study NCT03266315 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
Study NCT05619354 — intervention group
Intervention type: OTHER
Intervention: Survey study
Description: Participants will be asked to complete and evaluate the Dutch version of the Headache Disability Index. Validity (face validity, content validity, convergent validity with the RAND-36 and HIT-6) will be determined. Second, internal consistency and test-retest reliability will be evaluated.
Study NCT05349656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TQL block
Description: Ultrasonography-guided quadratus lumborum block (QLB) where we will infiltrate local anesthetic solution adjacent to the anterolateral aspect of the quadratus lumborum muscle
Study NCT05349656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: Ultrasound-guided local anesthetic infiltration will be injected in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
Study NCT05400343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care (control group)
Description: Following 24 hours from admission to the ICU, the standard care will be continued according to conventional ICU protocols~The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment.